Ad26.ZEBOV

Discontinued / Inactive

Developer: Janssen Vaccines & Prevention B.V.  |  Target Disease: Ebola

Program Status: Inactive / Discontinued

Reason: Registry status: TERMINATED

Stage at discontinuation: phase_3

Not in the latest registry fetch

The most recent ClinicalTrials.gov query no longer returns this candidate — usually because every trial grouped under it has completed, so it has dropped out of the active-status search. The record below is kept as it stood at the fetch of 2026-07-10 and has not been re-confirmed since. Check the linked trials directly for their current state.

Development discontinued.

Development Phase Discontinued / Inactive Primary Status
Platform Technology Viral vector Biologic Architecture
Target Indication Ebola Pathogen / Antigen
Last Verified 2026-07-10 Tier 1 Multi-Source Checked

Multi-Jurisdiction Regulatory Status

Official licensing, rolling submissions, or authorization status tracked across major health authorities.

Regulatory Authority Status & Details
US FDA Not Filed / Pre-submission
EMA (Europe) Not Filed / Pre-submission
Health Canada Not Filed / Pre-submission
TGA (Australia) Not Filed / Pre-submission

Progress and adoption outlook

Where this candidate sits on a fixed development ladder, and when a licence and a routine-use recommendation could follow in each jurisdiction, as scenario bands. Input grade: Discontinued or withdrawn; tracked, not projected.

60% of the laddernot projected
  1. Preclinical
  2. Phase 1
  3. Phase 1/2
  4. Phase 2
  5. Phase 2/3
  6. Phase 3
  7. Submitted to a regulator
  8. Under regulatory review
  9. Approved / authorised
  10. Recommended for routine use

Stopped at Phase 3

Discontinued. No adoption window is projected for a stopped programme.

Scientific Profile & Documentation

Platform Architecture
Viral vector
Lead Developer
Janssen Vaccines & Prevention B.V.
Next Expected Milestone
Primary completion (most advanced trial): 2021-12-13 (registry estimate)
Analyst & Development Notes
Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.
Primary Source Documentation
ClinicalTrials.gov NCT02661464 →

Registered Clinical Trials & Studies

Direct registry links to active, completed, or pivotal registration studies across phases.

NCT02661464 Discontinued / Inactive

Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

Status: Active / Ongoing • Expected Readout: 2021-12-13

Milestone Overview

  • Stage Verification
    Discontinued / Inactive confirmed as of 2026-07-10.
  • Target Milestone
    Primary completion (most advanced trial): 2021-12-13 (registry estimate)

Vaccine Data Navigator Candidate Profile Registry:

This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.